LIFETECH SCI to Acquire Approximately 96.46% Stake in Beijing Huayi Shengjie Technology for 1.8733 Billion Yuan

Stock News05-22

LIFETECH SCI (01302) announced that on May 22, 2026, the company intends to acquire approximately 96.46% of the equity in Beijing Huayi Shengjie Technology Co., Ltd. from the seller, AUT-VII HK Holdings Limited. The transaction consideration is approximately 1.8733 billion yuan, which will be settled by the company issuing convertible bonds to the seller. Upon completion of the transaction, Huayi Shengjie will become a non-wholly-owned subsidiary of the company, and its financial performance will be consolidated into the group's financial statements.

Huayi Shengjie is a medical device company primarily engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. Its products are mainly used for treating congenital heart defects and preventing cardiogenic embolic stroke. The company launched one of the first domestically produced congenital heart defect occluders in China in 2003 and introduced the country's first patent foramen ovale (PFO) occluder product in 2009. Huayi Shengjie holds competitive advantages in proprietary technology, market access, and research and development capabilities.

The board of directors believes that the acquisition aligns with the group's overall development strategy and will bring long-term benefits to the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148688057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 23:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148688057","market":"sh","top_or_hot":-1,"title":"LIFETECH SCI to Acquire Approximately 96.46% Stake in Beijing Huayi Shengjie Technology for 1.8733 Billion Yuan","media":"Stock News","content":"<p>LIFETECH SCI (01302) announced that on May 22, 2026, the company intends to acquire approximately 96.46% of the equity in Beijing Huayi Shengjie Technology Co., Ltd. from the seller, AUT-VII HK Holdings Limited. The transaction consideration is approximately 1.8733 billion yuan, which will be settled by the company issuing convertible bonds to the seller. Upon completion of the transaction, Huayi Shengjie will become a non-wholly-owned subsidiary of the company, and its financial performance will be consolidated into the group's financial statements.</p>\n<p>Huayi Shengjie is a medical device company primarily engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. Its products are mainly used for treating congenital heart defects and preventing cardiogenic embolic stroke. The company launched one of the first domestically produced congenital heart defect occluders in China in 2003 and introduced the country's first patent foramen ovale (PFO) occluder product in 2009. Huayi Shengjie holds competitive advantages in proprietary technology, market access, and research and development capabilities.</p>\n<p>The board of directors believes that the acquisition aligns with the group's overall development strategy and will bring long-term benefits to the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIFETECH SCI to Acquire Approximately 96.46% Stake in Beijing Huayi Shengjie Technology for 1.8733 Billion Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIFETECH SCI to Acquire Approximately 96.46% Stake in Beijing Huayi Shengjie Technology for 1.8733 Billion Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-22 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LIFETECH SCI (01302) announced that on May 22, 2026, the company intends to acquire approximately 96.46% of the equity in Beijing Huayi Shengjie Technology Co., Ltd. from the seller, AUT-VII HK Holdings Limited. The transaction consideration is approximately 1.8733 billion yuan, which will be settled by the company issuing convertible bonds to the seller. Upon completion of the transaction, Huayi Shengjie will become a non-wholly-owned subsidiary of the company, and its financial performance will be consolidated into the group's financial statements.</p>\n<p>Huayi Shengjie is a medical device company primarily engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. Its products are mainly used for treating congenital heart defects and preventing cardiogenic embolic stroke. The company launched one of the first domestically produced congenital heart defect occluders in China in 2003 and introduced the country's first patent foramen ovale (PFO) occluder product in 2009. Huayi Shengjie holds competitive advantages in proprietary technology, market access, and research and development capabilities.</p>\n<p>The board of directors believes that the acquisition aligns with the group's overall development strategy and will bring long-term benefits to the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工业大麻","start_time":0,"source_url":"","article_id":"1148688057","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148688057","pubTimestamp":1779463098,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIFETECH SCI (01302) announced that on May 22, 2026, the company intends to acquire approximately 96.46% of the equity in Beijing Huayi Shengjie Technology Co., Ltd. from the seller, AUT-VII HK...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1600":"工业大麻","01302":"先健科技","BK1100":"医疗保健设备","BK1583":"高瓴概念"},"translate_title":"先健科技将以18.733亿元收购北京华仪圣杰科技约96.46%股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01302":1},"content_text":"LIFETECH SCI (01302) announced that on May 22, 2026, the company intends to acquire approximately 96.46% of the equity in Beijing Huayi Shengjie Technology Co., Ltd. from the seller, AUT-VII HK Holdings Limited. The transaction consideration is approximately 1.8733 billion yuan, which will be settled by the company issuing convertible bonds to the seller. Upon completion of the transaction, Huayi Shengjie will become a non-wholly-owned subsidiary of the company, and its financial performance will be consolidated into the group's financial statements.\nHuayi Shengjie is a medical device company primarily engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. Its products are mainly used for treating congenital heart defects and preventing cardiogenic embolic stroke. The company launched one of the first domestically produced congenital heart defect occluders in China in 2003 and introduced the country's first patent foramen ovale (PFO) occluder product in 2009. Huayi Shengjie holds competitive advantages in proprietary technology, market access, and research and development capabilities.\nThe board of directors believes that the acquisition aligns with the group's overall development strategy and will bring long-term benefits to the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148688057","isCrawlerRequest":true}